ClinicalTrials.gg
CompletedNCT02327143Updated Aug 6, 2018Results posted

A Study of LY2835219 in Healthy Participants

A Phase 1 interventional study of LY2835219 and ¹³C₈-LY2835219 in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-06.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aim of this study is to compare how much of the study drug gets into the blood stream when it is given as a single oral dose and as an intravenous infusion (given directly into a vein via a small needle).

The study will also provide information on how well the study drug is tolerated when given as a capsule in combination with giving it intravenously, and information on any changes in heart function.

The study will last about 10 days. Screening is required within 28 days before study drug is given.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overtly healthy sterile males or surgically sterile females or females
  • Have a (BMI) of 18 to 32 kilogram per meter square (kg/m\^2)
  • Have given written approved by Lilly and the ethical review board (ERB) governing the site.
  • Participants who are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures

Exclusion criteria

Exclusion Criteria:

  • Have participated in a clinical trial involving product within the last 90 days
  • Have an abnormality in the 12-lead (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Have an abnormal blood pressure
  • Show evidence of (HIV), or
  • Have donated blood of more than 500 milliliters (mL) within the last month
  • Have consumed any sensitive CYP2B6 substrate drugs, any inhibitor or any CYP3A inducer, herbal supplements, grapefruits or grapefruit containing products, Seville oranges or Seville orange containing products, star fruits or star fruit containing products within 2 weeks prior to dosing or intend to consume during the study
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    200 mg LY2835219

    200 mg LY2835219 administered orally on day 1.

    Drug: LY2835219

  • Experimental
    0.4 mg ¹³C₈-LY2835219

    0.4 mg ¹³C₈-LY2835219 given intravenously (IV) for 15 minutes, starting approximately 6 hours after the oral dose.

    Drug: ¹³C₈-LY2835219

Interventions

  • Administered orally

  • Drug¹³C₈-LY2835219

    Administered IV

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Zero to Infinity [AUC(0-∞)] of LY2835219 and ¹³C₈-LY2835219

    Time frame: Predose, 2, 4, 6, 6.25, 6.5, 6.75, 7.25, 8.25,10, 12, 14, 24, 48, 72, 96,120, 144, 168,192 Hours Postdose

Secondary outcomes

  1. PK: Maximum Observed Concentration (Cmax) of LY2835219

    Time frame: Predose, 2, 4, 6, 6.25, 6.5, 6.75, 7.25, 8.25,10, 12, 14, 24, 48, 72, 96,120, 144, 168,192 Hours Postdose

  2. PK: Time of Maximum Observed Drug Concentration (Tmax) of LY2835219

    Time frame: Predose, 2, 4, 6, 6.25, 6.5, 6.75, 7.25, 8.25,10, 12, 14, 24, 48, 72, 96,120, 144, 168,192 Hours Postdose

07

Results

Posted Aug 6, 2018

Participant flow

Day 1: Time 0 Hrs to 6 Hrs
Participant flow — Day 1: Time 0 Hrs to 6 Hrs
Milestone200 mg LY2835219200 mg LY2835219 + 0.4 mg ¹³C₈-LY2835219
Started110
Completed110
Not completed00
Day 1: Time 6 Hrs - to Day 9
Participant flow — Day 1: Time 6 Hrs - to Day 9
Milestone200 mg LY2835219200 mg LY2835219 + 0.4 mg ¹³C₈-LY2835219
Started011
Completed011
Not completed00

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration-Time Curve From Zero to Infinity [AUC(0-∞)] of LY2835219 and ¹³C₈-LY2835219
Time frame:
Predose, 2, 4, 6, 6.25, 6.5, 6.75, 7.25, 8.25,10, 12, 14, 24, 48, 72, 96,120, 144, 168,192 Hours Postdose
Reported as:
Geometric mean · nanogram*h/milliliter (ng∙h/mL)
Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Zero to Infinity [AUC(0-∞)] of LY2835219 and ¹³C₈-LY2835219
nanogram*h/milliliter (ng∙h/mL)200 mg LY2835219200 mg LY2835219 + 0.4 mg ¹³C₈-LY2835219
Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Zero to Infinity [AUC(0-∞)] of LY2835219 and ¹³C₈-LY28352193730 ± 3115.4 ± 28
Statistical analysis
  • 200 mg LY2835219 vs 200 mg LY2835219 + 0.4 mg ¹³C₈-LY2835219 · Ratio of geometric least squares: 0.448 · 90% CI 0.395 to 0.508Absolute bioavailability of LY2835219 following the administration of 200 mg LY2835219 (oral) with 0.4 mg \[13C8\]-LY2835219 (IV).
SecondaryPK: Maximum Observed Concentration (Cmax) of LY2835219
Time frame:
Predose, 2, 4, 6, 6.25, 6.5, 6.75, 7.25, 8.25,10, 12, 14, 24, 48, 72, 96,120, 144, 168,192 Hours Postdose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
PK: Maximum Observed Concentration (Cmax) of LY2835219
nanogram per milliliter (ng/mL)200 mg LY2835219
PK: Maximum Observed Concentration (Cmax) of LY2835219114 ± 32
SecondaryPK: Time of Maximum Observed Drug Concentration (Tmax) of LY2835219
Time frame:
Predose, 2, 4, 6, 6.25, 6.5, 6.75, 7.25, 8.25,10, 12, 14, 24, 48, 72, 96,120, 144, 168,192 Hours Postdose
Reported as:
Median · hours
PK: Time of Maximum Observed Drug Concentration (Tmax) of LY2835219
hours200 mg LY2835219
PK: Time of Maximum Observed Drug Concentration (Tmax) of LY28352196.63 (6.50 to 8.25)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
200 mg LY2835219—0/11 (0%)3/11 (27.3%)
200 mg LY2835219 + 0.4 mg ¹³C₈-LY2835219—0/11 (0%)5/11 (45.5%)
Most frequent other events
Most frequent other events
Event200 mg LY2835219200 mg LY2835219 + 0.4 mg ¹³C₈-LY2835219
ConstipationGastrointestinal disorders0/113/11
VomitingGastrointestinal disorders1/112/11
HeadacheNervous system disorders2/111/11
Abdominal pain upperGastrointestinal disorders0/111/11
Dry mouthGastrointestinal disorders0/111/11
DyspepsiaGastrointestinal disorders0/111/11
NauseaGastrointestinal disorders1/110/11
Feeling coldGeneral disorders0/111/11
Decreased appetiteMetabolism and nutrition disorders1/110/11
DizzinessNervous system disorders0/111/11

Baseline characteristics

All participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)All Participants
Mean56.00 ± 8.00
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female3
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino0
Not Hispanic or Latino11
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White10
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)All Participants
United Kingdom11
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leeds, LS2 9LH, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2018, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2014
First posted
Dec 30, 2014
Start
Jan 2015
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Results first posted
Aug 6, 2018
Last update
Aug 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02327143
Responsible party
Sponsor
First posted
Dec 30, 2014
Start date
Jan 2015
Primary completion
Feb 2015
Completion
Feb 2015
Results posted
Aug 6, 2018
Last update
Aug 6, 2018

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion